- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04328181
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT) (SPEQUA)
This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.
Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints, earl/temporal bone, colorectal carcinosis.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Philippe DOUEK, Pr
- Phone Number: +33 04 72 07 18 83
- Email: douek@creatis.insa-lyon.fr
Study Contact Backup
- Name: Adeline MANSUY
- Phone Number: +33 04 72 11 51 70
- Email: adeline.mansuy@chu-lyon.fr
Study Locations
-
-
Avenue Doyen Lépine
-
Bron, Avenue Doyen Lépine, France, 69500
- Recruiting
- Hôpital Cardiologique Louis Pradel - Hospices Civils de Lyon
-
Contact:
- Philippe DOUEK, Pr
- Phone Number: 04 72 35 73 53
- Email: philippe.douek@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients presenting following one of following medical conditions:
- Asymptomatic type 1 or 2 diabetes as regard to cardiovascular risks
- Diabetic foot ulcer
- Adrenal glands lesions: Adrenal incidentaloma or hyperaldosteronism or macroadenoma
- Urinary stone(s)
- Known Coronary artery disease: Stent imaging or control of calcified plaques
- Diffuse Interstitial Lung Diseases: Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Ground Glass Opacification, Chronic Thromboembolic Pulmonary Hypertension
- Conductive hearing loss
- Brain stroke (late or post thrombectomy)
- Intracranial arteriovenous malformation treated with coils or Onyx
- Joints diseases in haemophilia
- Ear/temporal bone
- Colorectal carcinosis
- Dissection aortique de type A opérée ou de type B non opérée, hématome intramural
- Patient has accepted to participate to the study and has signed the written consent;
- Pre-menopausal women only: Negative urinary pregnancy test on the day of imaging before the administration of study drug;
- Patient is affiliated to the French social security
Exclusion Criteria:
- Contraindication to the use of iodine containing contrast media (including subjects with suspicion for/or known to have NSF) (if injection);
- History of severe allergic or anaphylactic reaction to any allergen including drugs and contrast agents (as judged by the investigator, taking into account the intensity of the event);
- History of delayed major or delayed cutaneous reaction to Iomeron injection
- Estimated Glomerular Filtration Rate (eGFR) value < 30 mL/min/1.73 m2 derived from a serum creatinine result within 1 month before the imaging for examinations with contrast agent.
- Any subject on hemodialysis or peritoneal dialysis;
- Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery);
- Pregnant or nursing (including pumping for storage and feeding);
- Patient under guardianship, curatorship or safeguard of justice.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SPCCT and standard DECT
Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g.
image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
|
For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:
The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quality of the images
Time Frame: Day 8
|
A single four-point scale will be used (1: unacceptable, 2: usable under limited conditions, 3: probably acceptable, 4: fully acceptable) based on the European guidelines on quality criteria for computed tomography
|
Day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic confidence graded
Time Frame: Day 8
|
The diagnostic confidence grade will be calculated on a four-point scale (1: insufficient, 2: poor, 3: average, 4: good).
|
Day 8
|
Subjective image quality graded
Time Frame: Day 8
|
It will be calculated on a five-point scale (1: poor, 2: fair, 3: average, 4: good, 5: excellent) for each following criterion: noise, artifacts and sharpness.
|
Day 8
|
CT Dose Index volumic (CTDIvol)
Time Frame: Day 8
|
To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures. The CTDI is an estimation of the dose delivered to the organs for each acquired section that is based on acquisition parameters of a water phantom with a 32 cm diameter. The value is expressed in milligray (mGy). |
Day 8
|
Dose Length Product (DLP)
Time Frame: Day 8
|
To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures. The DLP is obtained as follows: CTDI * length of body explored = value in mGy.cm. |
Day 8
|
Equivalent dose (mSv)
Time Frame: Day 8
|
To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures. The equivalent dose is obtained by multiplying the DLP to the specific organ conversion factor. |
Day 8
|
Quantitatively image quality : Noise
Time Frame: Day 8
|
The noise by selecting regions of interest (ROI) will calculated.
|
Day 8
|
Quantitatively image quality : Density
Time Frame: Day 8
|
The density (HU) by selecting regions of interest (ROI) will calculated.
|
Day 8
|
Quantitatively image quality : contrast-to-noise ratio
Time Frame: Day 8
|
The contrast-to-noise ratio (CNR) by selecting regions of interest (ROI) will calculated.
|
Day 8
|
Depiction of anatomical structures of interest
Time Frame: Day 8
|
Depiction of anatomical structures of interest will be graded on a four-point scale (1: visualization just possible, 2: unclear borders but different structures already visible, 3: very good visualization, well-defined anatomy, 4: perfect delineation of anatomy).
|
Day 8
|
Radiation dose
Time Frame: Day 8
|
An average radiation dose delivered to the patients for each clinical application will be calculated.
|
Day 8
|
Statistical comparison between SPCCT and DECT
Time Frame: Day 8
|
Statistical comparison between SPCCT and DECT will be performed over all images and anatomical structures globally and also for each clinical application of interest.
|
Day 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philippe DOUEK, Pr, Service de Radiologie, l'Hôpital Louis Pradel - Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Congenital Abnormalities
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Neuropathies
- Foot Diseases
- Endocrine Gland Neoplasms
- Musculoskeletal Diseases
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Coronary Disease
- Cardiovascular Abnormalities
- Nervous System Malformations
- Otitis
- Vascular Malformations
- Intracranial Arterial Diseases
- Urolithiasis
- Urinary Calculi
- Adrenocortical Hyperfunction
- Adrenal Gland Diseases
- Calculi
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Central Nervous System Vascular Malformations
- Nephrolithiasis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Coronary Artery Disease
- Diabetic Foot
- Foot Ulcer
- Lung Diseases
- Joint Diseases
- Arteriovenous Malformations
- Lung Diseases, Interstitial
- Kidney Calculi
- Hyperaldosteronism
- Intracranial Arteriovenous Malformations
- Ear Diseases
- Adrenocortical Adenoma
- Labyrinthitis
- Labyrinth Diseases
Other Study ID Numbers
- 69HCL19_0486
- ID-RCB (Other Identifier: 2023-A01937-38)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Spectral Photon Counting Computed Tomography (SPCCT)
-
Hospices Civils de LyonRecruiting
-
Balgrist University HospitalRecruitingStress Fracture Metatarsal | Lower Limb Fracture | Stress Fracture Foot | Stress Fracture Ankle | Stress Fracture of TibiaSwitzerland
-
Mayo ClinicNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Active, not recruiting
-
University Medical Center MainzNot yet recruitingCoronary Artery DiseaseGermany
-
Jonsson Comprehensive Cancer CenterRecruitingProstate Carcinoma | Recurrent Prostate CarcinomaUnited States
-
University Hospital, AntwerpCompleted
-
NRG OncologyNational Cancer Institute (NCI)RecruitingOral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Buccal Mucosa Squamous Cell Carcinoma | Floor of Mouth Squamous Cell Carcinoma | Gingival Squamous Cell Carcinoma | Hard Palate Squamous Cell Carcinoma | Lip Squamous Cell... and other conditionsUnited States, Canada
-
William Beaumont HospitalsThe Minestrelli Advanced Cardiac Research Imaging Center, Royal Oak, MichiganCompletedMyocardial Infarction | Chest Pain | Angina PectorisUnited States
-
M.D. Anderson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingStage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell CarcinomaUnited States